Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy

Chimeric Antigen Receptor (CAR)-based therapies offer a promising, targeted approach to effectively treat relapsed or refractory B cell malignancies. However, the treatment-related toxicity defined as cytokine-release syndrome (CRS) often develops in patients, and if uncontrolled, can be fatal. Grad...

Descripción completa

Detalles Bibliográficos
Autores principales: Thakar, Monica S., Kearl, Tyce J., Malarkannan, Subramaniam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006459/
https://www.ncbi.nlm.nih.gov/pubmed/32076597
http://dx.doi.org/10.3389/fonc.2019.01529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006459/
https://www.ncbi.nlm.nih.gov/pubmed/32076597
http://dx.doi.org/10.3389/fonc.2019.01529

Ejemplares similares